ArticleJAAPA : official journal of the American Academy of Physician Assistants2026
Acute coronary syndrome during active infusion of andexanet alfa.
Article in JAAPA : official journal of the American Academy of Physician Assistants, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractNow withdrawn from the US market, andexanet alfa was initially approved by the FDA in 2018 to reverse life-threatening bleeds associated with factor Xa (FXa) inhibitors, specifically apixaban and rivaroxaban. Observed effects of andexanet alfa include a reduction in anti-FXa activity resulting in hemostatic efficacy. However, thrombotic events including myocardial infarction and deep venous thrombosis, typically occurring 6 to 30 days after infusion, have also been observed. This case presents the first known patient to develop an ST-segment elevation myocardial infarction while actively receiving infusion of andexanet alfa, which was an approved therapy at the time of the patient's treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.